Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Company Overview

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.03 to $0.04
• 50-Day Range: $0.02 to $0.14
• 52-Week Range: $0.02 to $6.93
• Volume: 268,227 shs
• Average Volume: 8.05 million shs
• Market Capitalization: $1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.33
• Consensus Rating: Hold

Syros Pharmaceuticals Stock Analysis - MarketRank™

Syros Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Syros Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Syros Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($2.94) to ($2.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syros Pharmaceuticals has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SYRS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syros Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syros Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.88

Short Interest

There is no current short interest data available for SYRS.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

Only 3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYRS Stock Analysis - Frequently Asked Questions

How have SYRS shares performed this year?

Syros Pharmaceuticals' stock was trading at $0.2298 at the beginning of the year. Since then, SYRS stock has decreased by 83.1% and is now trading at $0.0388.
View the best growth stocks for 2025 here.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Thursday, October, 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08.
Read the conference call transcript.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Syros Pharmaceuticals IPO?

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Top institutional investors of Syros Pharmaceuticals include FNY Investment Advisers LLC. Insiders that own company stock include Jason Haas, Conley Chee, Timothy Tyson, David Roth, Richard A Young, Eric R Olson and Nancy A Simonian.
View institutional ownership trends.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include Salesforce (CRM), QUALCOMM (QCOM), Bank of America (BAC), Bristol-Myers Squibb (BMY), Pfizer (PFE), Twilio (TWLO) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 5/06/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYRS
• CIK: 1556263
• Web: www.syros.com
• Phone: (617) 744-1340
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.33
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +8,491.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-164,570,000.00
• Net Margins: N/A
• Pretax Margin: -25,275.20%
• Return on Equity: -3,369.56%
• Return on Assets: -97.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $386,000.00
• Price / Sales: 2.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 26,832,000
• Free Float: 23,542,000
• Market Cap: $1.04 million
• Optionable: Optionable
• Beta: 1.31